Some ARBs contain no NDMA or NDEA.Not all Torrent losartan-containing medications distributed in the U.S. are being recalled.

FDA alerts patients and health care professionals to Sandoz’s losartan potassium and hydrochlorothiazide recall of one lot due to NDEA.

This is Medicines are sometimes prescribed for conditions that are not mentioned in patient information leaflets. Distributing losartan containing NMBA up to 9.82 ppm, will help maintain adequate losartan supply while companies obtain approval for manufacturing processes that produce nitrosamine-free losartan for patients.FDA reminds patients taking recalled losartan to continue taking their current medicine until their pharmacist provides a replacement or their doctor prescribes a different medication that treats the same condition.
The FDA Alert(s) below may be specifically about amlodipine/hydrochlorothiazide/valsartan or relate to a group or class of drugs which include amlodipine/hydrochlorothiazide/valsartan.MedWatch Safety Alerts are distributed by the FDA and published by Drugs.com. Especially tell your doctor if you are taking:Know the medicines you take. 65862-470-30, We anticipate reposting the images once we are able identify and filter out images that do not match the information provided in the drug labels.
If you are a consumer or patient please visit This chemical is typically found in very small amounts in certain foods, drinking water, air pollution, and certain industrial processes.Amlodipine/Valsartan combination tablets and Amlodipine/Valsartan/Hydrochlorothiazide combination tablets are used for the treatment of high blood pressure. In the meantime, we continue to work with ARB manufacturers to remove all affected drugs from the market, and we work with API manufactures to fix their processes so they do not distribute affected API to drug product manufacturers.Our list of affected products and products without impurities remains available to the public, and we will update it when we have new information to share. If a manufacturer detects new or higher levels of impurities, they should fully evaluate the impurities and take action to ensure the product is safe for patients.RemedyRepack, a repackager of Torrent’s valsartan/amlodipine/hydrochlorothiazide (HCTZ) tablets, has also recalled.Additionally, FDA is releasing a gas chromatography-mass spectrometry In more ordinary terms, for example, one pound of bacon may contain 0.304-0.354 micrograms of NDMATest results from Hetero Labs show the amount of NDMA found in its valsartan API exceeds acceptable levels; although it is generally lower than the amount discovered in the API manufactured by Zhejiang.FDA is testing samples of valsartan API and finished products to confirm the extent and amount of NDMA and help inform the ongoing investigation. Untreated acute angle-closure glaucoma can lead to permanent vision loss.

Two of these companies, A-S Medication and RemedyRepack, may also distribute valsartan products not affected by the recall. When hydrochlorothiazide was administered without losartan to pregnant mice and rats during their respective periods of major organogenesis, at doses up to 3000 and 1000 mg/kg/day, respectively, there was no evidence of harm to the fetus.

Do not use losartan potassium and hydrochlorothiazide tablets for a condition for which it was not prescribed. This recall is an expansion of the recall initiated 12/31/18 The impurity detected in the finished drug product is N-nitrosodiethylamine (NDEA), which is a substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes, and has been classified as a probable human carcinogen as per International Agency for Research on Cancer (IARC) classification. If a manufacturer detects new or higher levels of impurity, they should take action to prevent changes to the product’s safety profile.

The FDA continues to work with API and drug manufacturers to ensure their products are not at risk for NDMA or NDEA formation. Drug Safety and Availability Through each step of our investigation, we’ve uncovered new information and taken a number of actions, including regulatory and advisory actions, where appropriate, to prevent the presence of unacceptable levels of these impurities. 65862-469-10, AurobindoPharma USA, Inc. is conducting a voluntary recall expansion of 38 lots of Valsartan and Amlodipine and Valsartan tablets to the consumer level due to … Additionally, FDA reminds patients taking this medication or any recalled ARB to continue taking their current medicine until their pharmacist provides a replacement or their doctor provides an alternative treatment option.

ARB medications that contain impurities above the published interim acceptable limits continue to be recalled, with certain exceptions.